OxSonics Limited A Finalist For “Best Emerging UK Medtech Company” Award

Oxford, UK – 1 September 2017 – OBN Ltd, the membership organisation supporting the UK’s innovative life sciences companies has announced the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health.

The OBN Awards remain proudly independent, celebrating innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late stage R&D companies as well as life sciences investors.

A judging panel comprising a range of industry experts has been assembled to decide the overall winner in each category, with the winning companies being announced at the OBN Awards Ceremony on Thursday 6th October at the Oxford Town Hall.

Dr Colin Story, Chief Executive Officer, commented: “We are delighted to have been shortlisted as a finalist in this prestigious award nomination category and is testament to the tremendous progress that the whole team at OxSonics has made during the past year.”

– ENDS –

About OxSonics Limited
OxSonics was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics SonoTran® drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics is based in Oxford, UK.

For more information please visit: www.oxsonics.com.

About OBN
OBN is the Membership organisation supporting and bringing together the UK’s innovative life sciences companies, corporate partners and investors. Its 400-plus member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities.  OBN is best known for its delivery of BioTrinity (12th edition: 23 – 25 April 2018), Europe’s leading life sciences investment and biopartnering conference. Further information about OBN’s tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN’s website www.obn.org.uk.

PDF version